Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Preliminary Efficacy of UCLH801 Cells in CDH17-Positive Advanced Malignant Solid Tumors
NCT06937567Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Dec 2024
- Primary completion
- Mar 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of UCLH801 in solid tumor (2 arms), sponsored by Zhejiang University. Primary endpoint: Safety of UCLH801 cells at 28 days. Started Dec 2024; status: recruiting.
02
Drugs
UCLH801
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06937567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06937567.